News

Lilly, in consultation with an independent data monitoring committee, recommended a ‘full clinical hold,’ because of safety concerns. Following the declaration of clinical hold no new or existing

Amgen has evaluated XGEVA (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer in ‘147 study Phase 3 trial. In the trial, the overall survival was similar

Inimex Pharma claims IMX942 is the first of a new class of drugs known as Innate Defense Regulators (IDRs), which improve survival, ameliorate tissue damage and reduce bacterial

Garabedian has been vice president of corporate strategy at Celgene Corporation since July 2007 ans was responsible for Celgene’s strategic and financial plan and supported the executive management

The platforms will provide improvements in clinical study timelines by accelerating data acquisition and the processing of final client reports in its Phase I clinics. PharmaNet, with the

McNeil Consumer Healthcare informed Health Canada that they are taking this action following consumer reports of foreign materials in the product, including metal and wood particles. McNeil is

In each case, the filing of the application will initiate an undisclosed milestone payment to MorphoSys. The therapeutic antibodies are being developed in the therapeutic areas of cancer

Administered every six months as a convenient subcutaneous injection, Denosumab reduces the risk of fractures at the spine, hip and other key non-vertebral sites. Amgen and GSK said

Following the launch Inspire will receive a related milestone payment of $1.25m in the fourth quarter of 2010 and is also entitled to receive payments based upon a